spironolactone has been researched along with medroxyprogesterone acetate in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (37.50) | 18.7374 |
| 1990's | 3 (18.75) | 18.2507 |
| 2000's | 3 (18.75) | 29.6817 |
| 2010's | 4 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ernst, B; Lill, MA; Vedani, A; Winiger, F | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Cusan, L; Labrie, C; Labrie, F; Lapointe, S; Plante, M | 1 |
| Begin, DJ; Labrie, F; Luthy, IA | 1 |
| Prior, JC; Vigna, YM; Watson, D | 1 |
| Schmidt, JB | 1 |
| Hauffa, BP; Havers, W; Stolecke, H | 1 |
| Raj, SG; Talbert, LM | 1 |
| Feuillan, PP | 1 |
| Bourguignon, JP; Kulin, HE | 1 |
| Azziz, R | 1 |
| Arias-Loza, PA; Blode, H; Elmore, SA; Ertl, G; Fritzemeier, KH; Hegele-Hartung, C; Hu, K; Maronpot, R; Muehlfelder, M; Pelzer, T | 1 |
| Forcier, M; Jain, J; Kwan, D | 1 |
1 review(s) available for spironolactone and medroxyprogesterone acetate
| Article | Year |
|---|---|
Polycystic ovarian disease.
Topics: Adrenal Hyperplasia, Congenital; Androgens; Chorionic Gonadotropin; Cimetidine; Clomiphene; Contraceptive Agents, Female; Contraceptive Agents, Male; Cyproterone; Cyproterone Acetate; Female; Follicle Stimulating Hormone; Humans; Luteinizing Hormone; Medroxyprogesterone; Medroxyprogesterone Acetate; Ovary; Ovulation Induction; Polycystic Ovary Syndrome; Spironolactone | 1984 |
15 other study(ies) available for spironolactone and medroxyprogesterone acetate
| Article | Year |
|---|---|
Impact of induced fit on ligand binding to the androgen receptor: a multidimensional QSAR study to predict endocrine-disrupting effects of environmental chemicals.
Topics: Benzhydryl Compounds; Binding Sites; Diethylstilbestrol; Endocrine System; Hydrocarbons, Chlorinated; Ligands; Models, Molecular; Molecular Conformation; Phenols; Phytoestrogens; Quantitative Structure-Activity Relationship; Receptors, Androgen; Testosterone; Thermodynamics; Xenobiotics | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Analysis of the androgenic activity of synthetic "progestins" currently used for the treatment of prostate cancer.
Topics: Adrenal Glands; Animals; Chlormadinone Acetate; Cyproterone; Cyproterone Acetate; Dihydrotestosterone; Flutamide; Male; Medroxyprogesterone; Medroxyprogesterone Acetate; Megestrol; Megestrol Acetate; Organ Size; Ornithine Decarboxylase; Progesterone Congeners; Prostate; Prostatic Neoplasms; Rats; Rats, Inbred Strains; Spironolactone | 1987 |
Androgenic activity of synthetic progestins and spironolactone in androgen-sensitive mouse mammary carcinoma (Shionogi) cells in culture.
Topics: Androgens; Animals; Cell Division; Chlormadinone Acetate; Dihydrotestosterone; Flutamide; Male; Mammary Neoplasms, Experimental; Medroxyprogesterone; Medroxyprogesterone Acetate; Megestrol; Mice; Progestins; Spironolactone; Tumor Cells, Cultured | 1988 |
Spironolactone with physiological female steroids for presurgical therapy of male-to-female transsexualism.
Topics: Adult; Combined Modality Therapy; Estrogens, Conjugated (USP); Follow-Up Studies; Gonadal Steroid Hormones; Humans; Male; Medroxyprogesterone; Medroxyprogesterone Acetate; Sex Characteristics; Spironolactone; Transsexualism | 1989 |
[The concept of the causal therapy of hirsutism].
Topics: Cimetidine; Cyproterone; Cyproterone Acetate; Hirsutism; Humans; Medroxyprogesterone; Medroxyprogesterone Acetate; Receptors, Androgen; Spironolactone | 1986 |
Short-term effects of testolactone compared to other treatment modalities on longitudinal growth and ovarian activity in a girl with McCune-Albright syndrome.
Topics: Androgen Antagonists; Body Height; Bone Development; Combined Modality Therapy; Cyproterone; Cyproterone Acetate; Drug Therapy, Combination; Female; Fibrous Dysplasia of Bone; Fibrous Dysplasia, Polyostotic; Follow-Up Studies; Humans; Infant; Medroxyprogesterone; Medroxyprogesterone Acetate; Ovarian Cysts; Ovarian Function Tests; Spironolactone; Testolactone | 1987 |
McCune-Albright syndrome.
Topics: Adolescent; Calcitriol; Diagnosis, Differential; Female; Fibrous Dysplasia, Polyostotic; Humans; Ketoconazole; Leuprolide; Male; Medroxyprogesterone Acetate; Octreotide; Ovariectomy; Propylthiouracil; Puberty, Precocious; Spironolactone; Testolactone; Thyroid Diseases | 1994 |
True or central precocious puberty.
Topics: Cyproterone Acetate; Female; Gonadotropin-Releasing Hormone; Humans; Ketoconazole; Male; Medroxyprogesterone Acetate; Puberty, Precocious; Spironolactone; Testolactone | 1994 |
The hyperandrogenic-insulin-resistant acanthosis nigricans syndrome: therapeutic response.
Topics: Acanthosis Nigricans; Adolescent; Contraceptives, Oral; Drug Therapy, Combination; Female; Humans; Hyperandrogenism; Insulin Resistance; Leuprolide; Medroxyprogesterone Acetate; Spironolactone | 1994 |
Differential effects of 17beta-estradiol and of synthetic progestins on aldosterone-salt-induced kidney disease.
Topics: Aldosterone; Androstenes; Animals; Blood Pressure; Epithelial Sodium Channels; Estradiol; Female; Hypertrophy; Kidney; Kidney Diseases; Medroxyprogesterone Acetate; Oxidative Stress; Progesterone Congeners; Proliferating Cell Nuclear Antigen; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Cytoplasmic and Nuclear; Sodium Chloride; Spironolactone | 2009 |
Medroxyprogesterone Acetate in Gender-Affirming Therapy for Transwomen: Results From a Retrospective Study.
Topics: Adult; Breast; Drug-Related Side Effects and Adverse Reactions; Estradiol; Estrogens; Female; Hair; Humans; Incidence; Male; Medroxyprogesterone Acetate; Middle Aged; Mineralocorticoid Receptor Antagonists; Retrospective Studies; Self Report; Spironolactone; Testosterone; Transgender Persons; Treatment Outcome | 2019 |